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Background: Blood CXCR5+CD4+ T cells are defined as circulating T follicular helper (TFH) cells, which is required
for effective humoral immunity. This study aimed to investigate the role of circulating TFH cells in patients with
chronic hepatitis B virus (CHB) infection.
Methods: The frequency and phenotype of circulating TFH cells were monitored by flow cytometry in CHB
patients and in healthy controls (HC). The expression of BCL-6, IL-21, IL-4, CXCR5, and IL-6R mRNA was analyzed
using real-time PCR. Serum HBsAg, HBeAg, HBeAb, HBV DNA loads, ALT and AST were determined. The potential
association of the frequency of TFH cells and their surface markers with clinical parameters was assessed.
Results: The frequency of CXCR5+CD4+ T cells was increased in CHB patients and positively correlated with ALT
and AST but not with HBV DNA loads. Moreover, an expansion of ICOS-, PD-1-, CD40L-, and IL-21R-expressing TFH
cells occurred in CHB patients, but failed to correlate with ALT, AST and HBV DNA loads. Interestingly, the frequency
of CXCR5+CD4+ T cells and ICOS+CXCR5+CD4+ T cells was significantly higher in HBeAg positive CHB patients than in
HC. Additionally, the percentages of CXCR5+CD4+ T cells were positively correlated with AST, and ICOS-expressing
CXCR5+CD4+ T cells were negatively correlated with HBV DNA loads. No significant differences in the frequency of
CXCR5+CD4+ T cells were observed between inactive carrier (IC) patients and healthy controls. However, ICOS-, PD-1-,
CD40L-expressing TFH cells were increased in IC patients and positively correlated with AST. Furthermore, the expres-
sion of BCL-6, IL-21, IL-4, CXCR5, and IL-6R mRNA in TFH cells was higher in CHB patients than in HC.
Conclusions: These data demonstrate that circulating TFH cells may participate in HBV-related immune responses. In
addition to the frequency of TFH cells, the phenotype of these cells plays an important role in CHB patients.
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Approximately 350 million people worldwide are carriers
of hepatitis B virus (HBV), and half a million to 1 million
of these carriers die from liver diseases each year [1].
Therapeutic management of chronic hepatitis B patients
can stop or slow the progression of the disease and reduce
complications, but it is impossible to eradicate HBV and
reverse liver damage [1,2]. The outcome of infection and
the pathogenesis of liver disease are determined by* Correspondence: hp_cq@163.com
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unless otherwise stated.dynamic interactions between the virus and the host im-
mune system [3]. Thus, elucidating the immune mecha-
nisms that underlie these interactions is critical. Previous
studies suggested that the innate and cellular immune re-
sponses are major contributors to HBV clearance [4].
However, the role of humoral immunity in controlling
HBV remains poorly characterized.
Antibody production by B cells is critical for the clear-
ance of pathogens and for the establishment of long-term
humoral immunity [5]. T follicular helper (TFH) cells are
the major CD4+ T cell subset that is essential for full B cell
responses, including germinal center reactions, isotype
class switching, and antibody affinity maturation [6]. No
unique markers of TFH cells have been reported, andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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several markers that are directly related to the functions of
these cells [6]. TFH cells express large amounts of B cell
lymphoma 6 (Bcl-6) [7], which is necessary and sufficient
for the development of TFH cells in vivo [8]. Chemokine
(C-X-C) receptor 5 (CXCR5) is transiently expressed on
CD4+ T cells during their interaction with peptide-MHC,
but TFH cells can be distinguished from other T cells by
their sustained expression of high levels of CXCR5 [9].
CXCR5 promotes the colocalization of T and B cells [10].
TFH cells express surface molecules that play functional
roles in T cell and B cell collaboration, such as inducible
costimulator (ICOS), programmed cell-death protein 1
(PD-1), and CD40 ligand (CD40L). TFH cells also secrete
interleukin 4 (IL-4) and interleukin 21 (IL-21), which are
cytokines that promote growth, differentiation, and class
switching in B cells [11].
The unique localization of TFH cells within germinal
centers is a fundamental feature of this subset of T cells
[12].However, it is difficult to obtain lymphoid tissue from
patients for research purposes. Therefore, a surrogate strat-
egy is required to assess the quality of TFH cell responses
in humans. CXCR5+CD4+ T cells in the blood may serve
as counterparts of TFH cells for this purpose. CXCR5
+CD4+ T cells are known as circulating TFH cells; these
cells share functional properties with TFH cells and appear
to represent the circulating memory compartment of TFH
cells [13-15]. In addition, several studies demonstrated that
CXCR5+CD4+ T cells derived from both the circulation
and germinal centers potently induce antibody production
during co-culture with B cells in vitro [14,16,17]. The role
of blood CXCR5+CD4+T cells in patients with autoimmun-
ity has been explored [13,14], but little is known about the
role of circulating CXCR5+CD4+ T cells in patients with
chronic HBV infection. In this study, we explored the fre-
quency and phenotype of circulating TFH cells in patients
with chronic HBV infection and examined the potential as-
sociation of CXCR5+CD4+ T cells with clinical parameters.
This study may provide novel insights regarding the role of
circulating CXCR5+CD4+ T cells in patients with chronic
HBV infection.
Results
Clinical data from subjects in the five groups
Table 1 presents the demographic and clinical characteris-
tics of subjects from the chronic HBV infection and HC
groups. A total of 38 patients with chronic HBV infection
were recruited, including 17 males and 21 females with
ages ranging from 7 to 60 years. The subjects were divided
into the following groups according to AASLD guidelines
[18]: HBeAg-positive chronic hepatitis B (HBeAg + CHB)
(n = 14); immune tolerant carrier (IT) (n = 8); inactive car-
rier (IC) (n = 10); and HBeAg-negative chronic hepatitis B
(HBeAg- CHB) (n = 6). In addition, 12males and 13females with ages ranging from 23 to 64 years were in-
cluded as controls. The patients with chronic HBV infec-
tion were comparable to the healthy controls with respect
to sex and age. All patients with chronic HBV infection
were positive for HBV DNA, and half of these patients
had elevated levels of ALT and/or AST. Notably, the
healthy controls were negative for HBV DNA and had
normal ALT and AST levels.
Significantly increased frequency of CXCR5+CD4+ T cells
in patients with chronic HBV infection compared to
healthy controls
To determine the potential role of peripheral CXCR5+CD4+
T cells in patients with chronic HBV infection, the fre-
quency of peripheral blood CXCR5+CD4+ T cells within the
CD4+ T cell population was monitored by flow cytometry
(Figure 1). The percentages of CXCR5+CD4+ T cells were
17.87% (2.95-88.03%) in the chronic HBV infection group
and 11.13% (2.92-34.48%) in the HC group. As shown in
Figure 1C, the frequency of CXCR5+CD4+ T cells was sig-
nificantly higher in patients with chronic HBV infection
than in the HC group (p < 0.05). To further characterize the
frequency of CXCR5+CD4+ T cells in patients with chronic
HBV infection, it was necessary to determine whether dif-
ferences existed between the chronic HBV infection sub-
group and the HC group. Interestingly, the percentages of
CXCR5+CD4+ T cells were greater in the HBeAg − positive
chronic hepatitis B group than in the HC group (p < 0.05)
(Figure 1D). In contrast, the frequency of CXCR5+CD4+ T
cells in IT, IC or HBeAg- CHB patients was not significantly
different from that observed in the healthy controls (p >
0.05) (Figure 1D). Moreover, no significant differences in the
proportions of CXCR5+CD4+ T cells were observed among
the chronic HBV infection subgroups (data not shown).
Increased expression of ICOS, PD-1, CD40L and IL-21R in
CXCR5+CD4+ T cells in patients with chronic HBV infection
A significantly higher frequency of CXCR5+CD4+ T cells
was observed in the chronic HBV infection group than
in the HC group. Thus, it was important to determine
whether the expression of markers that are typically as-
sociated with TFH cells were altered. TFH cells are dis-
tinguished from other cell types by the expression of ICOS,
PD-1, CD40L, IL-21R, CXCR5, and IL-21. The phenotype
of TFH cells was assessed in this study (Figure 2A). Notably,
the expression of ICOS was increased in CXCR5+CD4+ T
cells in patients with chronic HBV infection compared
to healthy controls (p < 0.05) (Figure 2B). More import-
antly, the percentages of ICOS+CXCR5+CD4+ T cells
were significantly higher in the HBeAg + CHB, IT, IC and
HBeAg- CHB groups compared to the HC group (p <
0.05) (Figure 2C). Likewise, differential expression of PD-1
was observed between the patients with chronic HBV in-
fection and the healthy subjects (p < 0.01) (Figure 2D). In
Table 1 The demographic and clinical characteristics of subjects
Parameters HC CHB (HBeAg+) IT IC CHB (HBeAg-)
Number 25 14 8 10 6
Age (years)
Mean ± SD 30.6 ± 10.6 27.9 ± 12.0 26.8 ± 6.7 46.1 ± 14.8 42.8 ± 12.2
Sex N (%)
Male 12(48.0) 5(35.7) 5(62.5) 5(50.0) 2(33.3)
Female 13(52.0) 9(64.3) 3(37.5) 5(50.0) 4(66.7)
HBV-DNA (log10 copies/mL)
Mean ± SD NA 6.5 ± 0.4 7.2 ± 0.8 2.0 ± 1.3 4.6 ± 0.2
ALT (U/L)
Mean ± SD ≤40 504.1 ± 635.3 26.1 ± 8.4 21.7 ± 9.9 118.5 ± 56.7
AST (U/L)
Mean ± SD ≤40 430.3 ± 657.6 23.6 ± 6.5 27.8 ± 9.3 58.3 ± 21.4
HBeAg/Anti-HBe 0/0 14/0 8/0 0/10 0/6
NA, not applicable; HC, healthy control; CHB(HBeAg+), HBeAg-positive chronic hepatitis B; IT, immune tolerant carrier; IC, inactive carrier; CHB(HBeAg-),
HBeAg-negative chronic hepatitis B.
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and IL-21R+ CXCR5+CD4+ T cells were higher in patients
with chronic HBV infection than in the healthy controls
(p < 0.01) (Figure 2F, H). Remarkably, significantly higher
levels of PD-1+CXCR5+CD4+ T cells, CD40L+CXCR5+CD4+
T cells, and IL-21R+ CXCR5+CD4+ T cells were observed in
the IT, IC and HBeAg- CHB groups than in the HC group
(p < 0.05) (Figure 2E, G, I). However, no significant differ-
ence in the proportions of PD-1+CXCR5+CD4+ T cells,
CD40L+CXCR5+CD4+ T cells, and IL-21R+ CXCR5+CD4+Figure 1 Fluorescence-activated cell sorter (FACS) analysis of the freq
chronic HBV infection patients. (A) Gating strategy. (B) The percentage o
groups. (C) The percentage of CXCR5+CD4+ T cells was significantly higher in
(D) Comparison of the frequency of CXCR5+CD4+ T cells in the IT, IC, CHB(HBe
with chronic HBV infection; IT, immune tolerant carrier; IC, inactive carrier; CHB
hepatitis B; PI, propidium iodide. The horizontal lines represent the median vaT cells were observed between the HBeAg +CHB group
and the HC group (p > 0.05) (Figure 2E, G, I). Further ana-
lysis of the chronic HBV infection subgroups revealed no
differences between the subgroups (data not shown).
Patients with chronic HBV infection exhibited
overexpression of BCL-6, CXCR5, IL-6R, IL-4, and IL-21
mRNA in CXCR5+CD4+ T cells
As previously discussed, the two groups exhibited differ-
ential expression of ICOS, PD-1, CD40L, and IL-21R.uency of peripheral blood CXCR5+CD4+ T cells in patients with
f circulating CXCR5+CD4+ T cells was compared between the two
patients with chronic HBV infection than in healthy controls (P < 0.05).
Ag+), CHB(HBeAg-) and HC groups. HC, healthy controls; HBV, patients
1, HBeAg-negative chronic hepatitis B; CHB2, HBeAg-positive chronic
lues (±SEM).
Figure 2 The phenotype of circulating TFH cells was assessed in patients with chronic HBV infection and in HC. (A) The expression of
ICOS, PD-1, CD40L and IL-21R by CXCR5+CD4+ T cells were detected by flow cytometry. At least 50,000 events were analyzed for each sample, and the
data represent different groups of samples from at least two independent experiments. (B), (D), (F) and (H) Comparison of the percentages of ICOS
+CXCR5+CD4+ T cells, PD-1+CXCR5+CD4+ T cells, CD40L+CXCR5+CD4+ T cells, and IL-21R+CXCR5+CD4+ T cells in the chronic HBV infection and HC
groups. (C), (E), (G) and (I) Comparison of the percentages of ICOS+CXCR5+CD4+ T cells, PD-1+CXCR5+CD4+ T cells, CD40L+CXCR5+CD4+ T cells, and
IL-21R+CXCR5+CD4+ T cells between the IT, IC, CHB(HBeAg+), CHB(HBeAg-) and HC groups. CHB1, HBeAg-negative chronic hepatitis B; CHB2,
HBeAg-positive chronic hepatitis B. Each data point represents an individual subject. *, p < 0.05; **, p < 0.01.
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itional markers that are associated with TFH cells is crit-
ical for an improved understanding of the role of TFH
cells. TFH cells rely on the expression of the master regu-
lator transcription factor Bcl-6. CXCR5+CD4+ T cells in
patients with chronic HBV infection significantly up-
regulated expression of Bcl-6 mRNA compared to healthy
controls (p < 0.01). IL-21 is a typical cytokine for TFH
cells; as expected, IL-21 expression was significantly differ-
ent between the chronic HBV infection and HC groups
(p < 0.05). Moreover, the mRNA expression of additional
markers that are associated with TFH cells was analyzed
using real-time PCR. The expression of IL-6R, IL-4 and
CXCR5 mRNA in circulating CXCR5+CD4+ T cells was
higher in patients with chronic HBV infection than in
healthy controls (p < 0.05) (Figure 3).Correlation of CXCR5+CD4+ T cells with clinical
parameters in patients with chronic HBV infection
Because of the high frequency of TFH cells and the up-
regulation of a number of molecules associated with
TFH cells in patients with chronic HBV infection, we
evaluated whether TFH cells were linked to clinical pa-
rameters. ALT is a commonly used clinical parameter
that is associated with the inflammatory response in
patients with chronic HBV infection, and AST is
screened to determine the grade of liver injury. The
percentage of CXCR5+CD4+ T cells positively corre-
lated with the levels of serum ALT and AST in patients
with chronic HBV infection (r = 0.485, p < 0.01 and r =
0.515, p < 0.01, respectively) (Figure 4A, B). However, no
significant correlation was found between the percent-
ages of ICOS+CXCR5+CD4+ T cells, PD-1+CXCR5+CD4+
Figure 3 mRNA expression levels were determined by real-time
PCR. Increased expression of BCL-6, CXCR5, IL-6R, IL-4, and IL-21
mRNA in CXCR5+CD4+ T cells in patients with chronic HBV infection
(n = 16) compared to healthy controls (n = 16). Data are presented as
the mean ± SD. *,p < 0.05; **, p < 0.01.
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+CXCR5+CD4+ T cells and the levels of serum ALT
and AST (data not shown). Additionally, the frequen-
cies of CXCR5+CD4+ T cells, ICOS+CXCR5+CD4+ T cells,
PD-1+CXCR5+CD4+ T cells, CD40L+CXCR5+CD4+ T
cells, and IL-21R+CXCR5+CD4+ T cells were not cor-
related with HBV DNA loads (data not shown). Sur-
prisingly, the percentage of CXCR5+CD4+ T cells in
HBeAg + CHB patients was positively correlated with AST
(r = 0.542, p < 0.05) (Figure 5A) but not with ALT or HBV
DNA levels (data not shown). Moreover, the frequencies
of ICOS+CXCR5+CD4+ T cells and PD-1+CXCR5+CD4+ T
cells in HBeAg + CHB patients were negatively correlated
with HBV DNA loads (r = −0.543, p < 0.05 and r = −0.543,Figure 4 The correlation between CXCR5+CD4+ T cells and clinical pa
between the percentage of CXCR5+CD4+ T cells and serum levels of ALT. (
serum levels of AST. (C) The correlation between the percentage of CXCR5
values of individual patients (n = 38) from three separate experiments.p < 0.05, respectively (Figure 5B, C). Further, the per-
centage of CXCR5+CD4+ T cells in IC patients was
not correlated with ALT, AST or HBV DNA loads
(data not shown). In contrast, the proportions of
ICOS+CXCR5+CD4+ T cells, PD-1+CXCR5+CD4+ T
cells, and CD40L+CXCR5+CD4+ T cells in IC patients
were positively correlated with AST (r = 0.698, p <
0.05; r = 0.858, p < 0.01; and r = 0.801, p < 0.01, re-
spectively) (Figure 6A, B, C).
Discussion
The role of TFH cells in infectious and autoimmune dis-
eases has attracted recent attention. The mechanisms by
which TFH cells develop and the mechanisms by which
TFH cells or their associated molecules regulate antibody
responses in humans remain largely unknown. Several
studies demonstrated that the frequency of CXCR5+CD4+
T cells was not significantly increased in patients with
autoimmune diseases, such as SLE [13], autoimmune thy-
roid disease [19], and juvenile dermatomyositis [14], com-
pared to healthy controls. In contrast, conflicting results
have been obtained concerning the existence of a signifi-
cantly higher frequency of CXCR5+CD4+ T cells in pa-
tients with chronic HBV infection than in the HC group
[20]. Consistent with previous studies, our findings dem-
onstrated that the percentages of CXCR5+CD4+ T cells
were increased in patients with chronic HBV infection
compared to healthy controls. The data obtained in this
study suggest that chronic HBV infection drives CXCR5
+CD4+ T cell differentiation because in addition to therameters in patients with chronic HBV infection. (A) The correlation
B) The correlation between the percentage of CXCR5+CD4+ T cells and
+CD4+ T cells and HBV DNA loads. Data were expressed as the mean
Figure 5 The correlation between CXCR5+CD4+ T cells and clinical parameters in HBeAg-positive chronic hepatitis B patients. (A) The
correlation between the percentage of CXCR5+CD4+ T cells and serum levels of AST. (B) The correlation between the percentage of ICOS+CXCR5+CD4+ T
cells and HBV DNA loads. (C) The correlation between the percentage of PD-1+CXCR5+CD4+ T cells and HBV DNA loads. Data were expressed as the mean
values of individual patients (n = 14) from three separate experiments.
Figure 6 The correlation between CXCR5+CD4+ T cells and clinical parameters in inactive carriers. (A) The correlation between the
percentage of ICOS+CXCR5+CD4+ T cells and AST. (B) The correlation between the percentage of PD-1+CXCR5+CD4+ T cells and AST. (C) The
correlation between the percentage of CD40L+CXCR5+CD4+ T cells and AST. Data were expressed as the mean values of individual patients
(n = 10) from three separate experiments.
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http://www.virologyj.com/content/11/1/54increased frequency of these cells, the phenotype of
CXCR5+CD4+ T cells is altered.
The function of TFH cells is closely related to a com-
bination of markers. In this study, the expression of
ICOS was increased in CXCR5+CD4+ T cells in patients
with chronic HBV infection compared to healthy con-
trols. ICOS is not expressed by resting T cells and is rap-
idly upregulated after TCR stimulation. Previous studies
demonstrated that ICOS was required for Bcl6 upregula-
tion and for the initiation of the TFH cell differentiation
program [21]. Reduced numbers of TFH cells were ob-
served in the absence of ICOS signals [22]. ICOS de-
livers costimulatory signals by binding to ICOS ligand
(ICOS-L) expressed on antigen presenting cells. In both
mice and humans, the interruption of the ICOS-ICOS-L
interaction leads to impaired GC reactions, Ab class
switching, and affinity maturation [22,23]. Differential
expression of PD-1 was also observed between the two
groups. PD-1 signaling plays a major role in inhibiting T
cell responses. Previous studies demonstrated that PD-1
was elevated during a viral infection to inhibit chronic-
ally activated T cells from causing immunopathology or
becoming autoreactive [24]. Accumulating evidence indi-
cates that PD-L1- and/or PD-L2-expressing B cells inter-
acted with PD-1+ TFH cells to regulate germinal center B
cell survival and the formation and affinity of long-lived
plasma cells [25]. We also found that the proportions of
CD40L+CD4+CXCR5+ and IL-21R+CD4+CXCR5+ cells
were higher in patients with chronic HBV infection than
in healthy controls. The CD40L/CD40 interaction pro-
motes germinal center formation, immunoglobulin isotype
switching, and somatic hypermutation of the Ig to en-
hance affinity for antigens, as well as the subsequent for-
mation of long-lived plasma cells and memory B cells [26].
BCL-6 was recently identified as a master regulator of
TFH differentiation. Constitutive expression of Bcl-6 drives
TFH differentiation in vivo [27]. Previous work demon-
strated that GC TFH cells expressed a high level of Bcl-6,
while blood CXCR5+CD4+ T cells failed to express elevated
levels of the Bcl-6 protein [28]. In contrast to previous stud-
ies, blood CXCR5+CD4+ T cells in patients with chronic
HBV infection exhibited significantly up-regulated levels of
Bcl-6 mRNA compared to healthy controls. IL-21 has been
reported to play a role in TFH cell formation and in B cell
growth, survival, and isotype switching [29-32]. Our data
demonstrated that IL-21 mRNA was highly expressed in
circulating TFH cells in patients with chronic HBV infec-
tion. This finding suggests that circulating TFH cells can
help naïve B cells to produce antibody via IL-21 in patients
with chronic HBV infection. The observation that TFH
cells produce IL-4 after parasite infection was confirmed by
several studies [33,34]. IL-4 expression by GC TFH cells
that lack other Th2 characteristics is important for murine
B cell IgG1 class switching.Our study reveals that circulating TFH cells may be
involved in HBV-related immune responses via tran-
scription factors in combination with induction signals
and secreted cytokines. We further clarify the relation-
ship between circulating TFH cells and clinical parame-
ters in patients with chronic HBV infection. The
percentage of CXCR5+CD4+ T cells was positively cor-
related with serum levels of ALT and AST. However,
the frequency of CXCR5+CD4+ T cells was not corre-
lated with HBV DNA loads. These findings indicate
that blood CXCR5+CD4+ T cells are associated with
HBV-related liver damage. TFH cells may participate
in the inflammatory response, but these cells have no
relationship with HBV DNA load. Moreover, no sig-
nificant correlations were observed between the per-
centage of ICOS+CXCR5+CD4+, PD-1+CXCR5+CD4+,
CD40L+CXCR5+CD4+, or IL-21R+CXCR5+CD4+ T cells
and serum levels of ALT, AST or HBV DNA loads. The
frequency of CXCR5+CD4+ T cells was positively corre-
lated with serum levels of ALT and AST, but no significant
correlation was found between phenotype and serum
levels of ALT and AST. Further studies are needed to de-
termine whether the expression of CXCR5+CD4+ T cells
varies at different stages of the chronic HBV infection
process. In this study, the frequency of CXCR5+CD4+ T
cells and ICOS+CXCR5+CD4+ T cells was significantly
higher in HBeAg + CHB patients than in HC, and the per-
centage of CXCR5+CD4+ T cells in HBeAg + CHB patients
was positively correlated with AST. In addition, the pro-
portion of ICOS+CXCR5+CD4+ T cells in HBeAg + CHB
patients was negatively correlated with HBV DNA loads.
Further, the frequency of ICOS+CXCR5+CD4+ T cells,
PD-1+CXCR5+CD4+ T cells, and CD40L+CXCR5+CD4+ T
cells in IC patients was positively correlated with AST.
Our findings reveal that TFH cells may reflect active im-
mune responses because TFH cells are specialized pro-
viders of B cell help and promote humoral responses
against viral infection. This positive correlation also sug-
gests that the frequency and phenotype of CXCR5+CD4+
T cells is associated with HBV-related liver damage.Conclusion
Our results demonstrated that the levels of CXCR5+CD4+
T cells and the expression of ICOS, PD-1, CD40L, and IL-
21R in CXCR5+CD4+ T cells were increased in patients
with chronic HBV infection compared to healthy controls.
Moreover, CXCR5+CD4+ T cells were positively correlated
with serum levels of ALT and AST in patients with
chronic HBV infection, indicating that circulating counter-
parts of TFH cells may be involved in HBV-related im-
mune responses. Further functional investigations of these
cells may elucidate the pathogenesis of chronic HBV
infection.
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Patients
A total of 38 patients with chronic HBV infection were
recruited from the outpatient service of the Second Af-
filiated Hospital of Chongqing Medical University from
July to November 2012, and 25 healthy volunteers were
selected as controls. Individual subjects with HBV infec-
tion were confirmed to be positive for both HBsAg and
detectable HBV virions for more than 6 months. Sub-
jects infected with the hepatitis A, C, D, or E viruses or
the human immunodeficiency virus and patients with a
history and clinical features of drug-induced liver injury,
alcoholic hepatitis, autoimmune diseases and steatohe-
patitis were excluded. All of the included patients were
naïve and had not been previously treated with nucleo-
side/nucleotide analog antiviral or immunomodulatory
drugs. This study conformed to the ethical guidelines of
the Declaration of Helsinki and was approved by the
Ethics Committee of the Second Affiliated Hospital of
Chongqing Medical University. All subjects provided
written informed consent.
Samples
Peripheral blood samples were obtained from individual
subjects with written informed consent. Levels of HBV
DNA were detected using a fully automated real-time
PCR machine and the luciferase quantitation detection
kit, with a detection limit of 300 copies/mL (Roche
Amplicor, Basel, Switzerland). Serum markers of HBV,
anti-HAV, anti-HCV and anti-HEV were determined via
the Roche electrochemical luminescence method using
an Architect i2000 system (Abbott Laboratories, Abbott
Park, IL, USA). Serum anti-HDV was analyzed by ELISA
according to the manufacturer’s instructions (Kehua Bio-
Engineering Co, Ltd, Shanghai, China). Serum levels of
AST and ALT were detected using the Automatic Bio-
chemistry Analyzer (Beckman LX-20, Beckman, USA).
Flow cytometry analysis
Five milliliters of heparinized peripheral venous blood
was obtained from either healthy volunteers or patients
with chronic HBV infection. After removing plasma, the
red blood cells were lysed using an NH4Cl lysis solution.
Flow cytometry analysis was performed on 106 cells per
tube using the following fluorochrome-conjugated anti-
bodies: anti-CD3–phycoerythrin (PE)–cyanine (CY) 7
(eBioscience, San Diego, CA, USA), anti- CD4–fluores-
cein isothiocyanate (FITC) (BD Company, San Jose, CA,
USA), anti- CXCR5–allophycocyanin (APC) (BD Com-
pany, San Jose, CA, USA), anti-ICOS–PE (BD Company,
San Jose, CA, USA), anti-PD1-PE (BD Company, San Jose,
CA, USA), anti-CD40L–PE (eBioscience, San Diego, CA,
USA), and anti-IL-21R-PE (BD Company, San Jose, CA,
USA). Isotype-matched control antibodies (BecktonDickinson, San Jose, USA) were used to correct nonspe-
cific binding. After staining for 30 min at 4°C, the cells
were washed twice with PBS containing 0.5% bovine
serum albumin and subsequently analyzed using a FACS
Canto II cytometer and FACSDiva software, version 4.1
(Becton Dickinson).MACS cell separation
CXCR5+CD4+ T cells were isolated from PBMCs using an
autoMACS to achieve >95% purity, as previously described.
The employed MACS Cell Separation Reagents contained a
CD4+ T cell biotin–antibody cocktail, a CXCR5-biotin-
antibody, and micro-beads. CD4+ Tcells were negatively se-
lected using a CD4+ T cell isolation kit (Miltenyi Biotec,
Germany), yielding populations of CD4+ cells with 96–99%
purity. Next, CXCR5+ T cells were separated from CD4+ T
cells on the AutoMACS via repetitive separation steps using
a positive selection kit (Miltenyi Biotec).
Real-time PCR
Total RNA was extracted from blood TFH cells using
Trizol (Invitrogen) according to the manufacturer’s in-
structions. The concentration and the purity of the RNA
were determined by absorbance at 260/280 nm, and
cDNA was synthesized using the PrimeScript RT reagent
Kit (TaKaRa, Japan). Relative levels of gene expression
were measured by real-time PCR using the SYBRGreen
master mix reagent in an ABI PRISM 7300 sequence
detection system. The following primers were used: GAPDH
(NSO_1236141_039, NSO_1236141_040, Invitrogen),
BCL-6 (HP 205513, Origene), CXCR5 (HP205521, Ori-
gene), IL-6R (HP200535, Origene), IL-4 (HP200556,
Origene), and IL-21 (HP214222, Origene). Amplifica-
tion began with an initial denaturation for 30 seconds
at 95°C followed by 40 cycles of denaturation at 95°C
for 5 seconds and annealing and extension at 60°C for
31 seconds. The plate was subsequently read. Each
sample was tested in triplicate, and the average values
were used for subsequent calculations. The expression
of each gene was normalized to the housekeeping gene
GAPDH, and expressed values relative to control were
calculated using the △△CT method. Amplified products
were visualized using a UV transilluminator in com-
bination with 1.2% agarose gel electrophoresis and
ethidium bromide staining.Statistical analysis
All statistical tests were performed using SPSS software,
version 17.0 (SPSS Inc., Chicago, IL, USA). Data were pre-
sented as the mean ± SD. The t-test was used to compare
two independent variables. Correlations between variables
were evaluated using the Pearson correlation test. A two-
tailed P < 0.05 was considered statistically significant.
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